Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

92979

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the European Medicines Agency's review of valproate and related substances and their use by pregnant women to report; and if he will make a statement.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	210191
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) completed its review of the risk of neurodevelopmental disorders in children exposed to valproate in the womb. PRAC has recommended strengthening the restrictions on the use of valproate. In particular PRAC has recommended that valproate should not be used to treat epilepsy and bipolar disorder in girls, women who can become pregnant or pregnant women unless other treatments are ineffective or not tolerated and that the need for continued treatment should be reviewed regularly. The PRAC recommendations will now be sent to the Member States’ Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for a final opinion in November. Healthcare professionals and patients will be informed of the new advice once the CMDh has reached a final opinion.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 15:19:41 answering member 4020 label Biography information for George Freeman
tabling member	4036 label Biography information for Luciana Berger

92585

registered interest
date	10/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding his Department has committed to dementia research in each of the next five years.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	209307
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>At the G8 dementia summit in December 2013, the G8 countries agreed to work together to tackle and defeat dementia. The declaration, built on the Prime Minister’s Dementia Challenge, announced the G8’s ambition to identify a cure or a disease-modifying therapy by 2025 and to increase collectively and significantly the amount of funding for dementia research.</p><p> </p><p> </p><p> </p><p>Investment in dementia research by the National Institute for Health Research (NIHR) has already more than doubled from £12.6 million in 2009-10 to £26.8 million in 2013-14.</p><p> </p><p> </p><p> </p><p>In March 2012, the Prime Minister’s challenge on dementia announced that the combined value of the NIHR, the Medical Research Council and the Economic and Social Research Council funding for research into dementia will increase from £26.6 million in 2009-10 to an estimated £66.3 million in 2014-15. The NIHR does not have a ring-fenced budget for dementia research and has not committed a specific amount for expenditure on dementia research in 2014-15 or in each of the next five years.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:10:43 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

91990

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants: Harlow
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many prescriptions were issued for antidepressant medication in Harlow constituency in each of the last 10 years.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	209512
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Information is not available in the format requested. The following table shows numbers of prescriptions issued for antidepressant medication for West Essex Primary Care Trust (PCT) from 2010-11 to 2012-13 and for West Essex Clinical Commissioning Group (CCG) for 2013-14. Data is not available at constituency level or prior to 2010-11.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="5"><p>Numbers of antidepressant prescription items written in the specified organisations and dispensed in the community by the specified financial years</p></td></tr><tr><td><p>Year</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012/13</p></td><td><p>2013-14</p></td></tr><tr><td><p>West Essex PCT</p></td><td><p>233,181</p></td><td><p>252,536</p></td><td><p>258,873</p></td><td><p>-</p></td></tr><tr><td><p>West Essex CCG</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>274,969</p></td></tr></tbody></table><p> </p><p><em>Source: </em>Health and Social Care Information Centre Prescribing Analysis and CosT tool (PACT) system</p><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p>1. The data in the table relate to prescriptions of items from the British National Formulary (BNF) section 4.3.</p><p> </p><p>2. The data available in PACT is a rolling 60-month dataset, so only the number of prescriptions in the last four full financial years is available.</p><p> </p><p>3. PACT covers prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK. For data at PCT level, prescriptions written by a prescriber located in a particular PCT but dispensed outside that PCT will be included in the PCT in which the prescriber is based. Prescriptions written in England but dispensed outside England are included.</p><p> </p><p>4. Prescriptions written in hospitals/clinics that are dispensed in the community, prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in PACT data. It is important to note this as some BNF sections have a high proportion of prescriptions written in hospitals that are dispensed in the community including, for example, BNF chapter 4, <em>Central Nervous System</em>. These prescriptions are not included in PACT data.</p><p> </p><p>5. Prescriptions are written on a prescription form known as a FP10. Each single item written on the form is counted as a prescription item.</p><p> </p><p>6. The PACT system uses the therapeutic classifications defined in the BNF. Information on why a drug is prescribed is not available in this dataset. Since drugs can be prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:38:10 answering member 4020 label Biography information for George Freeman
tabling member	3985 label Biography information for Robert Halfon

92003

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost-per-quality adjusted life year threshold used by the National Institute for Health and Care Excellence and its predecessor bodies to determine the cost-effectiveness of medicines has been in each year since 1999; and what that threshold has been in each year in real terms (a) using the gross domestic product deflator, (b) adjusting for health pay and price inflation and (c) adjusting for the health component of the consumer price index.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	209346
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) does not operate a fixed cost per Quality Adjusted Life Year (QALY) in the development of its technology appraisal guidance. NICE’s <em>Guide to the Methods of Technology Appraisal </em>explains that, for most technology appraisals, it uses a cost per QALY range of £20,000 to £30,000 in its decision-making that enables other factors to be taken into account. This range has remained unchanged since NICE was established in 1999.</p><p> </p><p> </p><p> </p><p>NICE’s technology appraisal methods guide contains further information on the way in which NICE takes the cost per QALY into account in the development of its guidance and is available at:</p><p> </p><p> </p><p> </p><p>www.nice.org.uk/article/pmg9/</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 16:15:41 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

92008

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents have been recorded by the NHS of Citalopram leading to the deterioration of a patient's health in the last five years.
tabling member constituency	Richmond Park
tabling member printed	Zac Goldsmith
uin	209345
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the Yellow Card Scheme.</p><p> </p><p><strong> </strong></p><p> </p><p>The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a doctor or patient suspects may have been due to a medicine. The MHRA has received a total of 1207 suspected ADR reports in association with citalopram between 1 January 2009 and 31 August 2014. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs. The number of reports received directly from the NHS cannot be determined.</p><p> </p><p> </p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 16:18:40 answering member 4020 label Biography information for George Freeman
tabling member	4062 label Biography information for Lord Goldsmith of Richmond Park

92239

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the development of a patient experience survey for HIV has been considered as part of NHS England's review of patient experience.
tabling member constituency	Chesham and Amersham
tabling member printed	Mrs Cheryl Gillan
uin	209664
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>NHS England is currently reviewing its programme of patient experience and outcomes data collection. The insight review aims to ensure that the data collected meets the needs of NHS England and its partners as effectively as possible. To inform this review, a steering group has been meeting quarterly to discuss priorities for data collection. This group includes a number of national stakeholder organisations in the health and care system; clinical commissioning groups (CCGs) and NHS trusts; the third sector and patient groups; and clinical representatives. The review is also being informed by interviews with patient experience data leads in CCGs and commissioning support units. A new insight strategy will be published by NHS England in spring 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 209665 209709 question first answered 15/10/2014 15:35:43 answering member 4020 label Biography information for George Freeman
tabling member	18 label Biography information for Dame Cheryl Gillan

92240

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patients: Surveys
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the timetable is for publishing the outcomes of NHS England's review of patient experience.
tabling member constituency	Chesham and Amersham
tabling member printed	Mrs Cheryl Gillan
uin	209665
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>NHS England is currently reviewing its programme of patient experience and outcomes data collection. The insight review aims to ensure that the data collected meets the needs of NHS England and its partners as effectively as possible. To inform this review, a steering group has been meeting quarterly to discuss priorities for data collection. This group includes a number of national stakeholder organisations in the health and care system; clinical commissioning groups (CCGs) and NHS trusts; the third sector and patient groups; and clinical representatives. The review is also being informed by interviews with patient experience data leads in CCGs and commissioning support units. A new insight strategy will be published by NHS England in spring 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 209664 209709 question first answered 15/10/2014 15:35:43 answering member 4020 label Biography information for George Freeman
tabling member	18 label Biography information for Dame Cheryl Gillan

92242

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will assess the effect of the National Institute for Health and Care Excellence's three-month end-of-life threshold on the number of treatments for advanced pancreatic cancer.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	209582
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Since the National Institute for Health and Care Excellence (NICE) issued its supplementary advice to its appraisal committees on the appraisal of life extending, end-of-life treatments in January 2009, NICE has not published final technology appraisal guidance on any treatments for advanced pancreatic cancer.</p><p> </p><p> </p><p> </p><p>NICE is currently developing technology appraisal guidance on two treatments for pancreatic cancer:</p><p> </p><p>- Abraxane (paclitaxel) in combination with gemcitabine for treating previously untreated metastatic adenocarcinoma of the pancreas (final guidance is expected in January 2015); and</p><p> </p><p>- Theraloc (nimotuzumab) for the first line treatment of metastatic pancreatic cancer (final guidance is expected in August 2015).</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:33:22 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

92257

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patients: Surveys
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress NHS England has made on its review of patient experience; and if he will make a statement.
tabling member constituency	Chesham and Amersham
tabling member printed	Mrs Cheryl Gillan
uin	209709
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>NHS England is currently reviewing its programme of patient experience and outcomes data collection. The insight review aims to ensure that the data collected meets the needs of NHS England and its partners as effectively as possible. To inform this review, a steering group has been meeting quarterly to discuss priorities for data collection. This group includes a number of national stakeholder organisations in the health and care system; clinical commissioning groups (CCGs) and NHS trusts; the third sector and patient groups; and clinical representatives. The review is also being informed by interviews with patient experience data leads in CCGs and commissioning support units. A new insight strategy will be published by NHS England in spring 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 209664 209665 question first answered 15/10/2014 15:35:43 answering member 4020 label Biography information for George Freeman
tabling member	18 label Biography information for Dame Cheryl Gillan

92258

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many drugs were approved by the Cancer Drugs Fund and subsequently rejected by NICE in the last 12 months.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	209753
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Since 1 September 2013, no cancer drugs have been added to the national list of approved cohort policies for drugs available through the Cancer Drugs Fund and subsequently not been recommended by the National Institute for Health and Care Excellence in final technology appraisal guidance.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:22:31 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales